Pharmaceuticals, Biotechnology and Life Sciences
Direct delivery of imatinib to the lungs in nonclinical species demonstrated increased lung exposure compared with oral or IV dosing…
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201100% (8/8) overall response rate and 63% (5/8)…
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201100% (8/8) overall response rate and 63% (5/8)…
Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe…
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine…
— New MARIPOSA Study Data Showed AD109 Statistically Significantly Improved Both Objective and Subjective Outcomes in OSA Patients — MARIPOSA Results…
Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and…
Submission based on data from the pivotal international Phase III CONTENT clinical program, also recently published in European Urology1CONTENT showed that…
12 of 16 voting-eligible advisors vote “no” (with two abstentions) on question, “given the available efficacy and safety data, do…
Early-stage data presented at the 26th Annual Meeting of the American Society for Gene and Cell Therapy demonstrate that therapy…